Provided by Tiger Trade Technology Pte. Ltd.

BEONE MEDICINES

212.800
+6.6003.20%
Volume:3.68M
Turnover:775.16M
Market Cap:328.14B
PE:142.79
High:213.000
Open:206.000
Low:203.800
Close:206.200
52wk High:235.600
52wk Low:153.000
Shares:1.54B
HK Float Shares:1.43B
Volume Ratio:0.96
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.490
ROE:14.66%
ROA:7.46%
PB:8.09
PE(LYR):142.79
PS:6.83

Loading ...

Movement Alert|BeOne Medicines Rises 3.23% in Regular Trading, Biotech Sector Rallies on Policy Tailwinds from National Essential Drug List Update

Market Focus
·
Jul 15

Movement Alert|BeOne Medicines Rises 3.19% in Regular Trading, Brukinsa MANGROVE Phase 3 Data and New Buy Rating Drive Momentum

Market Focus
·
Jul 10

BeiGene grants 33,388 ADS-linked RSUs to 215 employees, equal to 0.03% of share capital

Bulletin Express
·
Jul 08

BEIGENE Awards Aggregate 33,400 Restricted Stock Units Represented by American Depositary Shares

Stock News
·
Jul 08

BeOne Medicines — June 2026 Share Capital Steady; Option Grants Lift Potential Dilution, Public Float Intact

Bulletin Express
·
Jul 08

Movement Alert|BeOne Medicines Declines 3.1% in Regular Trading, Trading at HK$184.3

Market Focus
·
Jul 07

Movement Alert|BeOne Medicines Rises 3.17% in Regular Trading, Brukinsa Phase 3 MANGROVE Trial Positive Data Continues to Catalyze

Market Focus
·
Jul 06

Movement Alert|BeiGene Rises 3.49% in Regular Trading, Brukinsa Phase 3 Positive Data and Insurance Policy Catalysts Sustain Momentum

Market Focus
·
Jul 03

BEIGENE Shares Surge Over 4% on Positive Phase 3 Clinical Trial News for Zanubrutinib

Stock News
·
Jul 03

Movement Alert|BeOne Medicines Rises 3.35% in Regular Trading, Brukinsa Phase 3 Positive Data and Sector Rally Lift Shares

Market Focus
·
Jul 02

Market Insights: US Inflation Remains Elevated; Southbound Stock Connect Threshold May Have Risen to HKD 10.267 Billion

Stock News
·
Jul 02

BeOne Medicines' Brukinsa Shows 43% Risk Reduction in Mantle Cell Lymphoma Trial; Shares Down 3%

MT Newswires Live
·
Jul 01

BEIGENE Reports Positive Phase 3 Trial Results for BRUKINSA® in First-Line Treatment of Mantle Cell Lymphoma

Stock News
·
Jun 30

Movement Alert|BeOne Medicines Falls 3.21% in Regular Trading, Biotech Sector Collective Pullback Compounds Tax Payment Overhang

Market Focus
·
Jun 30

Movement Alert|BeOne Medicines Rises 3.01% in Regular Trading, Rebounding After Tax Payment Overhang Digested

Market Focus
·
Jun 29

BeOne Medicines Unit to Pay Additional Income Tax

MT Newswires Live
·
Jun 26

BEIGENE Subsidiary to Pay Approximately 446 Million Yuan in Back Taxes, No Penalty Involved

Stock News
·
Jun 26

BeOne Medicines to Pay RMB446 Million Tax Adjustment, Expense Slated for FY2026

Bulletin Express
·
Jun 26

Movement Alert|BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Indication FDA Filing Acceptance Continues to Catalyze

Market Focus
·
Jun 24

Movement Alert|BeOne Medicines Rises 3.04% in Regular Trading, FDA Acceptance of Tevimbra Esophageal Cancer Application Continues to Catalyze Rebound

Market Focus
·
Jun 23